Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shen, P.
Right arrow Articles by Morton, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shen, P.
Right arrow Articles by Morton, D. L.
Related Collections
Right arrow Surgery

Annals of Surgical Oncology, Vol 7, Issue 2 114-119, Copyright © 2000 by Society of Surgical Oncology


ARTICLES

Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma recurrences?

P. Shen, J. M. Guenther, L. A. Wanek and D. L. Morton
Department of Surgical Oncology and the Roy E Coats Research Laboratories of the John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California, USA.

BACKGROUND: Although more than 90% of the morbidity and mortality from localized cutaneous melanoma occurs in the first decade after initial surgical treatment, melanoma can recur after a 10-year disease-free interval (DFI) with fatal consequences. We reviewed our melanoma data base of more than 8,500 prospectively acquired patients to identify clinicopathological factors that affect the type, rate of occurrence, and outcome of disease recurring 10 years or more after surgical treatment of primary cutaneous melanoma. METHODS: From 1971 to 1997, 1907 melanoma patients treated at our cancer center reached or presented with a DFI of 10 years or more after surgical treatment of clinically localized melanoma. Of these, 217 (11%) patients had recurrences (mean DFI, 182 months). The sites of recurrence were local/in-transit in 26 (12%) patients, regional lymph nodes in 101 (47%) patients, and distant sites in 90 (41%) patients. RESULTS: Univariate and multivariate analysis, using patient age and sex, type of initial treatment, and the site, Breslow thickness, and Clark level of the initial tumor, showed that the type of treatment for the primary tumor was a significant (P = .0005) prognostic factor in the development of late nodal recurrence. Of the 217 patients who had recurrences, 172 (79%) had undergone wide local excision for their primary melanoma, and 45 (21%) had undergone wide local excision plus elective lymph node dissection (ELND). The rates of nodal recurrence were 53% (92 of 172) and 20% (9 of 45), respectively, a significant (P = .0001) difference. When all patients with a DFI of 10 years or more were stratified by type of initial treatment, the ELND group demonstrated a significant improvement in disease-free survival and overall survival. CONCLUSIONS: The risk of late-recurring nodal disease increases and the chance of long-term survival decreases when wide local excision is performed without ELND. With the advent of sentinel lymphadenectomy, ELND can be selectively performed only for those nodal basins with occult tumor cells, thereby decreasing operative morbidity but allowing identification and early removal of nodal micrometastases.


This article has been cited by other articles:


Home page
Ann. Surg. Oncol.Home page
L. Kretschmer, I. Beckmann, K.-M. Thoms, C. Mitteldorf, H. P. Bertsch, and C. Neumann
Factors Predicting the Risk of In-Transit Recurrence After Sentinel Lymphonodectomy in Patients With Cutaneous Malignant Melanoma
Ann. Surg. Oncol., August 1, 2006; 13(8): 1105 - 1112.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
C. Caraco, E. Celentano, S. Lastoria, G. Botti, P. A. Ascierto, and N. Mozzillo
Sentinel Lymph Node Biopsy Does not Change Melanoma-Specific Survival Among Patients with Breslow Thickness Greater than Four Millimeters
Ann. Surg. Oncol., March 1, 2004; 11(3_suppl): 198S - 202S.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. M. Thomas, J. Newton-Bishop, R. A'Hern, G. Coombes, M. Timmons, J. Evans, M. Cook, J. Theaker, M. Fallowfield, T. O'Neill, et al.
Excision Margins in High-Risk Malignant Melanoma
N. Engl. J. Med., February 19, 2004; 350(8): 757 - 766.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
O. Alonso, M. Martinez, L. Delgado, A. De Leon, D. De Boni, G. Lago, M. Garces, F. Fontes, J. Espasandin, and J. Priario
Staging of Regional Lymph Nodes in Melanoma Patients by Means of 99mTc-MIBI Scintigraphy
J. Nucl. Med., October 1, 2003; 44(10): 1561 - 1565.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the Society of Surgical Oncology.